Dashboard
Manage Tickers

KPTIKaryopharm Therapeutics Inc.

Nasdaq karyopharm.com


$ 0.83 $ 0.05 (5.88 %)    

Friday, 23-Aug-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.76 $ 5.15 (1.08 %)
DIA $ 411.97 $ 4.35 (1.07 %)
SPY $ 562.00 $ 5.91 (1.06 %)
TLT $ 98.37 $ 0.64 (0.65 %)
GLD $ 231.99 $ 2.65 (1.16 %)
$ 0.8335
$ 0.83 x 400
-- x --
-- - --
$ 0.62 - $ 1.95
546,298
na
103.92M
$ 1.09
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-29-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-02-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 02-17-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-03-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-04-2021 03-31-2021 10-Q
15 02-24-2021 12-31-2020 10-K
16 11-02-2020 09-30-2020 10-Q
17 08-04-2020 06-30-2020 10-Q
18 05-05-2020 03-31-2020 10-Q
19 02-26-2020 12-31-2019 10-K
20 11-04-2019 09-30-2019 10-Q
21 08-07-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 02-28-2019 12-31-2018 10-K
24 11-08-2018 09-30-2018 10-Q
25 08-07-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-15-2018 12-31-2017 10-K
28 11-02-2017 09-30-2017 10-Q
29 08-08-2017 06-30-2017 10-Q
30 05-04-2017 03-31-2017 10-Q
31 03-16-2017 12-31-2016 10-K
32 11-07-2016 09-30-2016 10-Q
33 08-04-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 03-15-2016 12-31-2015 10-K
36 11-09-2015 09-30-2015 10-Q
37 08-10-2015 06-30-2015 10-Q
38 05-11-2015 03-31-2015 10-Q
39 03-13-2015 12-31-2014 10-K
40 11-10-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-karyopharm-therapeutics-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Kary...
08/07/2024 20:15:08

HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $7 pr...

rbc-capital-reiterates-outperform-on-karyopharm-therapeutics-maintains-3-price-target
RBC Capital Reiterates Outperform on Karyo...
08/07/2024 16:23:15

RBC Capital analyst Brian Abrahams reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and maintains $3 price...

baird-maintains-outperform-on-karyopharm-therapeutics-lowers-price-target-to-5
Baird Maintains Outperform on Karyopharm T...
08/07/2024 15:49:11

Baird analyst Mitch Collett maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and lowers the price target fr...

karyopharm-revises-fy24-total-revenue-outlook-from-140m---160m-to-145m---160m-est-14544m
Karyopharm Revises FY24 Total Revenue Outl...
08/06/2024 11:35:01

karyopharm-therapeutics-q2-2024-gaap-eps-020-beats-030-estimate-sales-42786m-beat-36179m-estimate
Karyopharm Therapeutics Q2 2024 GAAP EPS $...
08/06/2024 11:32:59

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate ...

hc-wainwright--co-maintains-buy-on-karyopharm-therapeutics-lowers-price-target-to-7
HC Wainwright & Co. Maintains Buy on Karyo...
06/28/2024 17:28:55

HC Wainwright & Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and lowers the price...

hc-wainwright--co-reiterates-buy-on-karyopharm-therapeutics-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Kary...
06/03/2024 10:26:09

HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $8 pr...

karyopharm-on-saturday-presented-updated-exploratory-subgroup-analyses-from-siendo-study-on-advanced-or-recurrent-tp53-wild-type-endometrial-cancer-at-asco-2024
Karyopharm On Saturday, Presented Updated ...
06/02/2024 18:37:52

karyopharm-therapeutics-files-for-shelf-registration-of-up-to-458m-shares-of-common-stock-by-selling-stockholders
Karyopharm Therapeutics Files For Shelf Re...
05/30/2024 20:48:20

- SEC Filing

hc-wainwright--co-reiterates-buy-on-karyopharm-therapeutics-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Kary...
05/09/2024 10:53:41

HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $8 pr...

karyopharm-announces-refinancing-transactions-148m-of-existing-convertible-notes-due-in-2025-to-be-exchanged-for-111m-of-new-convertible-notes-due-in-2029-and-warrants-issues-new-100m-senior-secured-term-loan-due-in-2028a
Karyopharm Announces Refinancing Transacti...
05/08/2024 11:39:20

karyopharm-therapeutics-reaffirms-2024-revenue-guidance-of-140m-160m-versus-consensus-of-14652m-including-us-xpovio-net-product-revenue-guidance-of-100m-120m
Karyopharm Therapeutics Reaffirms 2024 Rev...
05/08/2024 11:39:20

karyopharm-therapeutics-q1-2024-gaap-eps-032-beats-033-estimate-sales-33126m-miss-34473m-estimate
Karyopharm Therapeutics Q1 2024 GAAP EPS $...
05/08/2024 11:38:06

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate ...

karyopharm-announces-presentations-in-endometrial-cancer-and-myelofibrosis-at-the-2024-american-society-of-clinical-oncology-annual-meeting
Karyopharm Announces Presentations In Endo...
04/24/2024 20:42:32

Invited to Present Updated Endometrial Cancer Data During Special Session "ASCO Plenary Series: Rapid Abstract Updates"...

onco360-selected-as-the-preferred-national-specialty-pharmacy-partner-for-karyopharms-product-xpovio-a-first-in-class-xpo-1-inhibitor
Onco360 Selected As The Preferred National...
03/13/2024 20:38:15

Onco360®, the nation's largest independent Oncology Pharmacy, is now the national specialty pharmacy network partner for Ka...

hc-wainwright--co-maintains-buy-on-karyopharm-therapeutics-lowers-price-target-to-8
HC Wainwright & Co. Maintains Buy on Karyo...
03/01/2024 12:10:52

HC Wainwright & Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and lowers the price...

karyopharm-sees-2024-total-revenue-140m-160m-vs-15202m-est
Karyopharm Sees 2024 Total Revenue $140M-$...
02/29/2024 12:31:56

karyopharm-therapeutics-q4-2023-gaap-eps-036-misses-030-estimate-sales-3375m-miss-3540m-estimate
Karyopharm Therapeutics Q4 2023 GAAP EPS $...
02/29/2024 12:31:15

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimat...

earnings-scheduled-for-february-29-2024
Earnings Scheduled For February 29, 2024
02/29/2024 10:15:24

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

karyopharm-therapeuticss-earnings-a-preview
Karyopharm Therapeutics's Earnings: A Preview
02/28/2024 19:01:25

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION